Neutralizing antibody persistence in pediatric travelers from non-JE-endemic countries following vaccination with IXIARO® Japanese encephalitis vaccine: An uncontrolled, open-label phase 3 follow-up study
| Autor: | Elizabeth D. Barnett, Susanne Eder-Lingelbach, Christian Taucher, Deborah J Mills, Tomas Jelinek, Sigrid Kiermayr, Katrin L. Dubischar, Vera Kadlecek, Duellyn Pandis, Jakob P. Cramer, Daniela Reiner |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty Adolescent Endemic Diseases 030231 tropical medicine Booster dose Antibodies Viral Persistence (computer science) 03 medical and health sciences 0302 clinical medicine medicine Humans 030212 general & internal medicine Japanese encephalitis vaccine Child Encephalitis Japanese Neutralizing antibody Encephalitis Virus Japanese biology Japanese Encephalitis Vaccines business.industry Australia Public Health Environmental and Occupational Health medicine.disease Antibodies Neutralizing United States Europe Clinical trial Vaccination Titer Infectious Diseases Child Preschool biology.protein Female business Encephalitis Follow-Up Studies medicine.drug |
| Zdroj: | Travel Medicine and Infectious Disease. 34:101616 |
| ISSN: | 1477-8939 |
| DOI: | 10.1016/j.tmaid.2020.101616 |
| Popis: | Background In an initial study among children from non-Japanese encephalitis (JE)-endemic countries, seroprotection rates remained high 6 months after completion of the primary series with IXIARO®. Methods In this open-label follow-up study, a subset of 23 children who received a 2-dose primary series of IXIARO® in the parent study, were evaluated for safety and neutralizing antibody persistence for 36 months. Results Seroprotection rates (SPRs) remained high but declined from 100% one month after primary immunization to 91.3% at month 7 and 89.5% at month 36. Geometric mean titers (GMTs) declined considerably from 384.1 by day 56–60.8 at month 36. No long-term safety concerns were identified. Conclusions The substantial decline in GMT observed in this study, together with previously published data on children vaccinated with IXIARO® support the recommendation for a booster dose in children who remain at risk of JE from 1 year after the primary series of IXIARO®, consistent with the recommendation for adults. Clinical trial registry number NCT01246479 . |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect